checkAd

     145  0 Kommentare mCig Projects Major Revenue Boost in 2020, Subsidiary BRXX Clinical Outlines Business Plan - Seite 2

    The company expects to market the plan through insurance brokers and is conservatively projecting $1 to $2 million in revenue from BRRX Clinical during its first year of operation. This is in addition to the $1.3 million in CBD product orders announced on January 17. New revenue is also expected from the independent pharmacy network as they conduct the aforementioned clinical trials, and from an anticipated CBD cosmetics line to be released later in the year.

    Paul Rosenberg, CEO of mCig, Inc., stated: “The clinical subscription service, once launched, could potentially create a significant new revenue stream for mCig. It puts mCig/Bare Roots into a category nothing like any existing CBD company or insurance services provider.”

    About MCIG Group

    Headquartered in Jacksonville, Florida, mCig, Inc. (MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands.

    The Company has been featured in media nationwide, including CNBC, Bloomberg, TheStreet.com. For more information, visit www.mciggroup.com.

    Visit us on Facebook @ https://www.facebook.com/mCigInc/

    Follow us on Twitter @mcigInc

    About BareRoots Rx Inc.

    The company focused on the development and commercialization of OTC, science-driven, botanical nutrigenetics, that target the endocannabinoid system. BareRoots Rx Inc. also delivers high-quality consumer and OTC THC-free CBD products that promote overall health and well being as well as state-of-the-art testing and analytics capabilities to our customers.

    Forward-Looking Statements

    This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent the Company’s current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company’s management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: potential, expect, look forward, believe, dedicated, building, or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by the Company herein are often discussed in filings the Company makes with the United States Securities and Exchange Commission (SEC) available at www.sec.gov and on the Company’s website at www.mciggroup.com.

    CONTACT: Contact:
    mCig, Inc.
    Paul Rosenberg
    paul@mciggroup.org
    
    Seite 2 von 2



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    mCig Projects Major Revenue Boost in 2020, Subsidiary BRXX Clinical Outlines Business Plan - Seite 2 JACKSONVILLE, FL, Jan. 27, 2020 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE – mCig, Inc. (MCIG), a vertically integrated company focused on the development and commercialization of OTC, science-driven, botanical nutrigenetics targeting the endocannabinoid …